DJNJ3 Stock Overview
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Johnson & Johnson Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1,300.00 |
| 52 Week High | US$1,716.00 |
| 52 Week Low | US$1,138.00 |
| Beta | 0.46 |
| 1 Month Change | 0% |
| 3 Month Change | 0% |
| 1 Year Change | 10.17% |
| 3 Year Change | 400.00% |
| 5 Year Change | n/a |
| Change since IPO | 641.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| DJNJ3 | AR Pharmaceuticals | AR Market | |
|---|---|---|---|
| 7D | 0% | 2.2% | 5.9% |
| 1Y | 10.2% | -23.2% | 85.1% |
Return vs Industry: DJNJ3 exceeded the AR Pharmaceuticals industry which returned -20.5% over the past year.
Return vs Market: DJNJ3 underperformed the AR Market which returned 91.5% over the past year.
Price Volatility
| DJNJ3 volatility | |
|---|---|
| DJNJ3 Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 7.5% |
| 10% most volatile stocks in AR Market | 9.3% |
| 10% least volatile stocks in AR Market | 5.1% |
Stable Share Price: Data is not available.
Volatility Over Time: Insufficient data to determine DJNJ3's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1886 | 138,100 | Joaquin Duato | www.jnj.com |
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Johnson & Johnson Fundamentals Summary
| DJNJ3 fundamental statistics | |
|---|---|
| Market cap | AR$418.56t |
| Earnings (TTM) | AR$15.02t |
| Revenue (TTM) | AR$94.83t |
27.9x
P/E Ratio4.4x
P/S RatioIs DJNJ3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DJNJ3 income statement (TTM) | |
|---|---|
| Revenue | US$88.82b |
| Cost of Revenue | US$27.04b |
| Gross Profit | US$61.79b |
| Other Expenses | US$47.72b |
| Earnings | US$14.07b |
Last Reported Earnings
Dec 29, 2024
Next Earnings Date
Apr 15, 2025
| Earnings per share (EPS) | 5.84 |
| Gross Margin | 69.56% |
| Net Profit Margin | 15.84% |
| Debt/Equity Ratio | 51.2% |
How did DJNJ3 perform over the long term?
See historical performance and comparisonDividends
3.0%
Current Dividend Yield84%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 11:28 |
| End of Day Share Price | 2025/03/12 00:00 |
| Earnings | 2024/12/29 |
| Annual Earnings | 2024/12/29 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Johnson & Johnson is covered by 57 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Charles Butler | Barclays |
| Matt Miksic | Barclays |